Site Map. Text Size. Search MU Research.
Office of Grant Writing & Publications.

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)

Limited Submission Announcement

PLEASE READ: Internal Procedures for Limited Submissions

Agency:

National Institutes of Health (NIH) | National Institute of Neurological Disorders and Stroke (NINDS)

Web Address:

https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-024.html

Post Date:

07/05/17

Amount:

The Maximum allowable direct cost per year for a NIH NeuroNEXT site will be $200,000. Maximum 5 year project period.

Campus Deadline:

07/24/2017

External Deadline(s):

September 1, 2017 | 5:00PM CT

Notes:

Only one Clinical Site application per institution is allowed. 


The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries.  Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials.


Although a LOI is not required to be submitted to the sponsor, it is encouraged, please see the guidelines for more information.

 

All limited submission announcements can be tracked by deadline via the Calendar at research.missouri.edu or by announcement date via the Limited Submissions listing at http://research.missouri.edu/lsas/.